Patents Assigned to Bayer
  • Publication number: 20220259228
    Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1- and/or TASK-3-blocking properties.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 18, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Martina DELBECK, Michael Hahn, Thomas Müller, Klemens Lustig, Johanna Anlahr, Udo Albus, Doris Gehring, Björn Rosenstein, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter
  • Patent number: 11414432
    Abstract: The present invention relates to novel fused bicyclic heterocycle derivatives of formula (I) in which B1, B2, B3, B4, R1, R4, R5, R6 and n have the meanings mentioned above, to agrochemical formulations comprising the compounds of formula (I) and to their use as acaricides and/or insecticides for controlling animal pests, especially arthropods and in particular insects and arachnids.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 16, 2022
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Dominik Hager, Ruediger Fischer, Laura Hoffmeister, Matthieu Willot, Kerstin Ilg, Ulrich Goergens
  • Patent number: 11414714
    Abstract: The present invention relates to means, methods and kits for the specific detection of the causing agent of powdery mildew on grapes, the fungus Erysiphe necator. More specifically, the methods according to the invention are quantitative methods based on quantitative Polymerase Chain Reaction.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 16, 2022
    Assignee: Bayer SAS
    Inventors: Patrice Dubournet, Semcheddine Cherrad, Sébastien Vacher
  • Publication number: 20220249456
    Abstract: The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).
    Type: Application
    Filed: February 16, 2022
    Publication date: August 11, 2022
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandra RAUSCH, Stefan Joachim JODL, Jörn KRÄTZSCHMAR, Ulrich BOTHE, Nicole SCHMIDT
  • Patent number: 11406751
    Abstract: A method for the automatic determination of a contrast agent protocol for a contrast agent-enhanced medical imaging method is described. The method includes an overview recording of a region of interest of an object under examination. In addition, an image recording protocol including a plurality of recording parameters is defined on the basis of the overview recording. Furthermore, recording time points are determined for a plurality of z-positions of the region of interest on the basis of the image recording protocol. In addition, the structures acquired with the overview recording are assigned to the recording time points determined. Finally, a contrast agent protocol including the temporal course of a contrast agent injection curve is defined as a function of the acquired structures and the assigned recording time points. A contrast agent protocol determination device is also described, as well as an imaging medicinal device.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: August 9, 2022
    Assignees: SIEMENS AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Thomas Flohr, Gregor Jost, Hubertus Pietsch
  • Patent number: 11406107
    Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: August 9, 2022
    Assignees: Bayer CropScience LP, Spogen Biotech Inc.
    Inventors: Damian Curtis, Brian Thompson
  • Publication number: 20220241261
    Abstract: The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.
    Type: Application
    Filed: December 7, 2021
    Publication date: August 4, 2022
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich BOTHE, Antje Margret WENGNER, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Roland NEUHAUS
  • Publication number: 20220241255
    Abstract: The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 4, 2022
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Peter Kolkhof, Peter Sandner
  • Patent number: 11401254
    Abstract: The present disclosure relates to substituted thiophene carboxamides and analogues thereof of formula (I) that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 2, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: David Bernier, Stéphane Brunet, Jérémy Dufour, Thomas Knobloch, Lionel Nicolas, Tomoki Tsuchiya
  • Patent number: 11401278
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 2, 2022
    Assignees: The Broad Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Laura Furst, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven J. Ferrara, Guo Wei, Patrick R. McCarren, Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning, Katrin Nowak-Reppel
  • Publication number: 20220235013
    Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 28, 2022
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars WORTMANN, Brice SAUTIER, Knut EIS, Hans BRIEM, Niels BOHNKE, Franz VON NUSSBAUM, Roman HILLIG, Benjamin BADER, Jens SCHRODER, Kirstin PETERSEN, Philip LIENAU, Antje Margret WENGNER, Dieter MOOSMAYER, Qiuwen WANG, Hans SCHICK
  • Publication number: 20220232815
    Abstract: The present invention relates to the application of plant protection agents, fertilisers and/or pesticides by means of a (preferably portable) sprayer or a small appliance (such as, for example, a bicycle tyre sealant injector). The present invention relates to a monitoring module with which existing sprayers can be equipped in order to control, track and/or document the spraying process. The present invention further relates to a method, a system and a computer program product for monitoring spraying processes.
    Type: Application
    Filed: May 25, 2020
    Publication date: July 28, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Volker GUTSMANN, Mayer WALTER
  • Publication number: 20220234996
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Application
    Filed: April 18, 2022
    Publication date: July 28, 2022
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Fey, Philipp Rubenbauer, Kai Lovis, Britta Olenik, Julia Küsel, Felix Spindler
  • Publication number: 20220227729
    Abstract: The present invention relates to compounds of formula (1) in which A, U and R1 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: May 14, 2020
    Publication date: July 21, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Duy NGUYEN, Knut EIS, Jeremie Xavier MORTIER, Hans BRIEM, Clara CHRIST, Anders Roland FRIBERG, Benjamin BADER, Patrick STEIGEMANN, Volker BADOCK, Jens SCHRÖDER, Franziska SIEGEL, Dieter MOOSMAYER
  • Patent number: 11389585
    Abstract: A pressure jacket configured for connecting to an injector head of a fluid injector has an open distal end, an open proximal end, and a sidewall defining a throughbore extending between the distal end and the proximal end along a longitudinal axis. The throughbore is configured for receiving at least a portion of a syringe. The pressure jacket has at least one syringe retaining element positioned at least partially within the throughbore. The at least one syringe retaining element is configured for engaging at least a portion of the syringe during pressurized delivery of fluid from the syringe to prevent or limit a distal movement of the syringe relative to the pressure jacket.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: July 19, 2022
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Michael Spohn, Kevin Cowan, Barry Tucker, Michael McDermott
  • Patent number: 11390592
    Abstract: A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and then with a calcium salt the calcium complex is produced in high purity. During the crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of the modification A of the compound of the formula (I) is used in the production of Gadovist.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: July 19, 2022
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 11390594
    Abstract: The disclosure provides for methods for preparing 2-cyanoimino-1,3-thiazolidine, which is an important building block for the preparation of crop protection active ingredients and pharmaceuticals. To this end, the disclosure provides for more efficient and improved methods of preparing 2-cyanoimino-1,3-thiazolidine.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: July 19, 2022
    Assignee: BAYER CROPSCIENCE LP
    Inventors: Shekhar Kulkarni, Eric Rivadeneira
  • Patent number: 11390589
    Abstract: The invention relates to substituted phenylpyrimidines of general formula (I), to their agrochemically acceptable salts (I), and to the use thereof in the field of plant protection.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 19, 2022
    Assignee: BAYER Aktiengesellschaft
    Inventors: Hartmut Ahrens, Birgit Kuhn, Stefan Schnatterer, Dirk Schmutzler, Hansjoerg Dietrich, Anu Bheemaiah Machettira, Elisabeth Asmus, Elmar Gatzweiler
  • Publication number: 20220218677
    Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN
  • Publication number: 20220218695
    Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular diazabicyclically substituted imidazo [1,2-a]pyrimidine derivatives and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN